 |
|
Breast Cancer Trial Results
1. Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 09/16/2008, Reviewed: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
2. Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
3. Osteoporosis Drug Raloxifene Does Not Protect Against Coronary Heart Disease, But Reduces Breast Cancer Risk
(Posted: 08/28/2006, Updated: 07/17/2008) - The drug raloxifene (Evista®) did not prevent heart problems in postmenopausal women with, or at high risk for, coronary heart disease, according to the July 13, 2006, issue of the New England Journal of Medicine.
4. Zoledronic Acid Improves Early Breast Cancer Treatment
(Posted: 06/19/2008, Reviewed: 09/16/2008) - The addition of zoledronic acid (Zometa) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
5. Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
1 2 3 4 Next >
|
|
|
